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Abstract
Neovascularization is essential for tumor growth. We have previously reported that the chemokine receptor CXCR2
is an important regulator in tumor angiogenesis. Here we report that the mobilization of bone marrow (BM)–
derived endothelial progenitor cells (EPCs) is impaired in CXCR2 knockout mice harboring pancreatic cancers.
The circulating levels of EPCs (positive for CD34, CD117, CD133, or CD146) are decreased in the bone marrow
and/or blood of tumor-bearing CXCR2 knockout mice. CXCR2 gene knockout reduced BM-derived EPC prolifera-
tion, differentiation, and vasculogenesis in vitro. EPCs double positive for CD34 and CD133 increased tumor
angiogenesis and pancreatic cancer growth in vivo. In addition, CD133+ and CD146+ EPCs in human pancreatic
cancer are increased compared with normal pancreas tissue. These findings indicate a role of BM-derived EPC in
pancreatic cancer growth and provide a cellular mechanism for CXCR2 mediated tumor neovascularization.
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Introduction
Endothelial progenitor cells (EPCs) originate mainly from the bone
marrow–derived cells with the ability to differentiate into mature endo-
thelial cells and contribute to blood vessel formation. The bone marrow
consists of many cell types [1], of which EPCs, pericyte progenitor cells
[2], myeloid progenitor cells [3], dendritic progenitor cells [4], and
tumor-associated macrophages [5,6] have been involved in tumor vas-
culogenesis and promotion of tumor growth. Whereas some types of
BM-derived cells contribute to tumor neovascularization indirectly
by providing structural support, EPCs play a central role in tumor
vasculogenesis. Initially, EPCs were identified in vasculogenesis during
embryogenesis but are now recognized to be important to vessel for-
mation in adulthood as well. Since EPCs were first isolated as CD34+
cells from human peripheral blood in 1997 [7], increasing evidence
demonstrated the role of EPC-mediated postnatal vasculogenesis in
various pathologic conditions including cardiovascular disease, wound
healing, and tumor neovascularization. In general, EPCs express three
surface markers CD34, CD133, and vascular endothelial growth factor
receptor 2 (VEGFR2).These cells characterize the early functional angio-
blast in the bone marrow. In addition, CD117, CD146, VE-cadherin,
and Tie-2 are also expressed on EPCs [8–10]. Recent evidences dem-
onstrated that BM-derived EPCs play an important role in tumor
neovascularization, tumor growth, and metastasis [10,11]. Tumor neo-
vascularization is a complex process. It is composed of angiogenesis by
sprouting of local endothelial cells and vasculogenesis by BM-derived
EPCs. The functional role of EPCs in tumor neovascularization has
been demonstrated in several cancer models including lung cancer,
lymphoma, breast cancer, melanoma, insulinoma, and brain tumor
[12–17]. By using the EPC defective Id1+/−Id3−/− mice, Lyden et al.
[12] demonstrated that EPCs are necessary for tumor vasculogenesis
and growth in mouse lung cancer and lymphoma. The BM-derived
EPCs incorporated into early stage tumor vessel and contributed to lung
cancer, breast cancer, and melanoma growth [13,14]. Moreover, Kaplan
et al. and Gao et al. [15] established an important role of EPCs in lung
metastasis of breast cancer. In a spontaneous insulinoma model, Spring
et al. [16] showed that EPCs incorporated into the tumor vessel and
contributed to the late stage of tumor growth. Du et al. [17] observed
recruitment of hypoxia-inducible 1–induced BM-derived EPCs into
tumor site and initiation of the angiogenic switch by EPCs in an ortho-
topic brain tumor model.
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Chemokines with a C-X-C cystein motif have angiogenic func-
tion and are involved in tumor growth and metastasis [18,19]. We
and others have shown that the CXC chemokine ligands CXCL5
(ENA-78) and CXCL8 (IL-8) interact with its common receptor
CXCR2 stimulating angiogenesis, involved in tumor growth and
metastasis in broad types of cancer including colon cancer, lung can-
cer, and pancreatic cancer [18–24]. The tumor-promoting effect of
the CXCL5/CXCL8/CXCR2 axis has been shown to signal through
activation of NF-κB and phosphorylation of mitogen-activated kinases
and phosphoinositide-3 kinase [21,22]. However, the cellular and
molecular mechanisms of CXCL5/CXCL8/CXCR2–mediated angio-
genesis and tumor growth are not fully understood.
Although the contribution of EPC to tumor neovascularization has
been demonstrated in several types of cancer, the role of BM-derived
EPC in pancreatic adenocarcinoma and the regulation of EPC mobili-
zation by CXCR2 in tumor neovascularization have not been reported.
The aim of this study was to determine the role of CXCR2 on reg-
ulation of EPC mobilization and function. Our data showed that
BM-derived EPCs stimulated vasculogenesis and pancreatic cancer
growth. EPCs are mobilized by pancreatic cancer cells. CXCR2 gene
knockout impaired EPC mobilization and reduced EPC proliferation,
differentiation, and neovascularization.
Materials and Methods
Cell Lines and Reagents
Mouse pancreatic cancer cells harboring a Kras mutation (G12D)
[25] were a kind gift from Dr Ashok Saluja (University of Minnesota).
The cell line was maintained in culture as an adherent monolayer in
RPMI supplemented with 10% fetal bovine serum. CD34, CD117,
CD133, CD146, and isotype IgG control antibodies for flow cytome-
try were purchased from eBioscience (San Diego, CA). Antibodies to
human CD133 or CD146 for immunohistochemistry were obtained
from Abcam (Cambridge, MA). Anti–mouse CD31 antibody was from
Angio-Proteomie (Boston, MA).
Patient Specimens
Nine cases of paired pancreatic tumor/normal pancreas and eight
cases of unpaired tumors or normal pancreas (formalin-fixed, paraffin-
embedded) samples from 1989 to 2005 were obtained through the
University of California at Los Angeles (UCLA), Departments of
Surgery and Pathology. This study was approved by the Institutional
Review Board at the UCLA, School of Medicine.
Mice
CXCR2 knockout mice were generated by crossing CXCR2 hetero-
zygous mice ( Jackson laboratory) on C57 mouse background. Geno-
typing analysis was done using mouse tail DNA. Polymerase chain
reaction (PCR) primers were as follows: CXCR2 wild type, 5′-GGT
CGT ACT GCG TAT CCT GCC TCA G and 3′-TAG CCA TGA
TCT TGA GAA GTC CAT G; and CXCR2 mutant, 5′-CTT GGG
TGG AGA GGC TAT TC and 3′-AGG TGA GAT GAC AGG AGA
TC. Tail DNA was extracted by a genotyping preparation kit, and
PCR was carried out using the 2× Taq PCR Premix (Bioland Scientific,
San Diego, CA). PCR products were separated on a 2% agarose gel.
All animal housing, care, and experiments were performed in accor-
dance with institutional guideline and approved by the UCLA Institu-
tional Animal Care and Use Committee.
In Vitro Cell Proliferation Assay
Bone marrow (BM) was flashed out from tibias and femurs of mice,
washed with Dulbecco modified Eagle medium containing 5% FBS.
Red blood cells were lysed with RBC lysis buffer (Sigma, St Louis,
MO). After washing with PBS, mononuclear cells (105) were collected
and cultured in suspension with endothelial growth medium (EGM;
Lanzo, Allendale, NJ) for 6 days. Cell growth was measured by cell
counting with Trypan blue.
In Vitro Cell Differentiation and Angiogenesis Assay
BM mononuclear cells (2 × 104) were seeded into 24-well culture
plate coated with fibronectin or Matrigel and cultured with EGM with
or without mouse pancreatic cancer–conditioned medium (PCCM).
After 4 to 6 days, the plate was examined for differentiated cells or
capillary tube formation and photographed. Total tube length was de-
termined by image analysis software (Image J; National Institutes of
Health, Bethesda, MD). The qualitative difference in tube formation
was examined. Each assay was done in duplicate, and each experiment
was repeated three times. The total length of capillary tube in wild
type and gene knockout cell culture was measured in five areas with
highest capillary tube density.
Flow Cytometry Analysis and Cell Sorting
Mononuclear cells from mouse blood or bone marrow were incu-
bated with fluorescence-conjugated antibodies (fluorescein isothio-
cyanate (FITC) for CD34, CD117, and CD146; phycoerythrin (PE)
for CD133) or isotype-matched IgG controls on ice for 30 minutes,
washed with PBS, and followed by flow cytometry on a FACScan
cytometer (Becton Dickinson). For cell sorting, mononuclear cells of
bone marrow were stained with fluorescence-conjugated antibody
(CD34-FITC and CD133-PE), and EPCs with double-positive for
CD34 and CD133 were sorted by FACS StarPlus flow cytometer
(Becton Dickinson). Flow cytometry data were analyzed using FCS
Express software (De Novo, Los Angeles, CA).
Immunohistochemistry
Immunohistochemical staining was performed as previously de-
scribed [26]. Briefly, sections (4 μm) from formalin-fixed paraffin-
embedded tissues were deparaffinized in xylene. Unmasking of antigens
was performed by incubating the sections in 0.01 M citrate buffer pH
6.0 in a microwave. Endogenous peroxidase was blocked by incubat-
ing sections with 3%H2O2. After blocking with serum and incubation
with the primary antibody overnight at 4°C, sections were washed with
PBS and incubated with biotinylated secondary antibody for 30 min-
utes at room temperature. Immunoreactivity was detected using the
ABC kit (Vector, Burlingame, CA) or Envision kit (DAKO, Carpinteria,
CA) for anti–mouse CD31. CD133 or CD146 staining was scored with
a percentage of stromal cells with positive immunoreactivity. Micro-
vascular density was determined by counting of CD31-positive blood
vessels in three areas with the highest blood vessel density. Staining data
were reviewed by two independent observers.
Pancreatic Cancer Growth in Mice
Mouse pancreatic cancer cells harboring a common Kras (G12D)
mutation were mixed with Matrigel and implanted subcutaneously
or orthotopically into the pancreas of 4- to 6-week-old CXCR2−/−,
CXCR2+/− or wild-type mice. Four weeks later, the mice were killed,
harvested tumors were measured, and mouse blood and bone marrow
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were collected. Tumors were fixed in 10% formalin and processed for
histopathology or immunohistochemistry. Tumor volume was calculat-
ed by the following formula: tumor volume = 4/3 × πA/2 × B/2 × C/2,
where A is the tumor’s length, B is the width, and C is the height.
Statistical Analysis
Statistical comparisons were made by Student’s t test or χ 2 test.
P ≤ .05 was deemed significant.
Results
Circulating EPC Level in Mouse BM and Blood
We first wanted to determine the EPC population in BM and
blood of mice by FACS analysis. BM from 4-week-old CXCR2−/−
mice and wild-type littermates was collected. The number of CD34+
cells is slightly lower in CXCR2−/− mice than in CXCR2+/+ mice
(8.5% vs 10%; Figure 1, A and B). However, a four-fold increase in
CD133+ cells and approximately two-fold increase in CD34+CD133+
cells were observed in CXCR2−/− mice compared with CXCR2+/+
mice (7.8% vs 1.8% and 5.2% vs 2.9%; Figure 1, A and B). We
then determined the EPC levels in adult mice. FACS analysis was
performed for CD34-, CD117-, CD133-, and CD146-positive cells
on BM or blood from 12-week-old wild-type mice. We observed
detectable but various levels of CD34+, CD117+, CD133+, and
CD146+ EPCs, with a low level of CD133+ and CD146+ EPCs in
the blood of wild-type adult mice (Figure 1C).
We examined the expression of CXCR2 in BM of wild-type and
CXCR2-deficient mice (Figure 1D). The BM of CXCR2+/+ mouse
containing 34.5% CXCR2-positive cells. The number of CXCR2-
positive cells decreased to 22.5% in CXCR2+/− and was undetectable
in CXCR2−/− mice.
EPC Mobilization Is Decreased in CXCR2−/− Mice
in Response to Tumor Challenge
To analyze EPC mobilization in response to the pancreatic cancer
challenge, we injected mouse pancreatic cancer cells into the pan-
creas of 4- to 6-week-old CXCR2+/+ and CXCR2−/− mice. BM or
blood was collected 4 to 7 weeks after tumor transplantation for FACS
analysis. In BM, the numbers of CD34+, CD117+, and CD146+ cells
were decreased in CXCR2−/−mice compared to CXCR2+/+ mice (Fig-
ure 2, A–D), whereas the number of CD133+ cells was approximately
0.5-fold higher in CXCR2−/− mice than in CXCR2+/+ mice (2.6% vs
Figure 1. Circulating levels of EPC- or CXCR2-positive cells in mice by flow cytometry analysis. EPC levels in bone marrow or blood of
4-week-old CXCR2+/+ (A) or CXCR2−/− (B) and 12-week-old wild-type mice (C). The number in the dot plot represents the percentage
of positive cells (left upper, CD133+; right upper, double CD34+, and CD133+, right low; CD34+). BL indicates blood. (D) CXCR2-
positive cells in CXCR2+/+ (solid, thick, and red), +/− (solid, thin, and green), and −/− (dash dot, blue) mice. Histogram represent one
of the mice analyzed; n = 3–4 mice per group.
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1.8%; Figure 2C ). The rates of decrease for CD34+, CD117+, and
CD146+ cells varied from two- to three-fold in CXCR2−/− mice. Next,
we analyzed EPC levels in the blood of CXCR2+/+ and CXCR2−/−
mice. We observed slightly decreased CD34+ and CD117+ cells in
CXCR2−/− mice. However, the level of CD133+ and CD146+ cells
is decreased by 10- and 5-fold, respectively, in CXCR2−/− mice. These
results indicate that the mobilization of CD34+, CD117+, CD133+,
and CD146+ EPCs is impaired in CXCR2−/− mice.
Figure 2. EPC levels in BM or blood of mice challenged with pancreatic cancer cells by flow cytometry analysis. (A) CD34+ EPCs in BM
or blood of CXCR2+/+ or CXCR2−/− mice. (B) CD117+ EPCs in BM or blood of CXCR2+/+ or CXCR2−/− mice. (C) CD133+ EPCs in
BM or blood of CXCR2+/+ or CXCR2−/−mice. (D) CD146+ EPCs in BM or blood of CXCR2+/+ or CXCR2−/−mice. The number on the
right upper corner represents the percentage of positive cells. The red solid line is the EPC marker staining; black dashed line is the
isotype control staining. Histogram represent one of the mice analyzed; n = 3–4 mice per group.
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CXCR2 Gene Knockout Reduced Proliferation,
Differentiation, and Capillary-Like Structure
Formation of BM-Derived Cells
To evaluate the growth rate of BM-derived EPC, BM cells were
cultured with endothelial growth medium for 6 days, and cell prolif-
eration was determined by cell count (Figure 3A). The cell number
in CXCR2+/− cells (5.6 × 105/ml) was decreased and further reduced
in CXCR2−/− (2.4 × 105/ml) compared with CXCR2+/+ cells (7.2 ×
105/ml, P < .01 vs CXCR2−/− cells; Figure 3A). To determine the
function of CXCR2 on EPC maturation and vasculogenesis, we per-
formed an in vitro assay to determine the differentiation and the
function of BM-derived cells. BM mononuclear cells were plated
on fibronectin- (Figure 3, B–G ) or Matrigel-coated plate (Figure 4,
A–C ) and cultured with EGM or EGM mixed with PCCM. After
culturing for 4 days, CXCR2+/+ cells showed spindle cell–type dif-
ferentiation in a small percentage of cells (Figure 3B). In contrast,
no morphologically differentiation was observed in CXCR2+/−
or CXCR2−/− cells on fibronectin-coated plates (Figure 3, C and
D). PCCM largely increased cell differentiation of CXCR2+/+ and
CXCR2+/− cells (Figure 3, E and F ) but not in CXCR2−/− cells
(Figure 3G ). We observed capillary tube–like structures formed in
CXCR2+/+ and CXCR2+/− cells cultured with PCCM on Matrigel
at day 6 (Figure 4, A and B) but not in CXCR2−/− cell cultures
(Figure 4C ). The ability of capillary tube formation is significantly
decreased in CXCR2+/− and CXCR2−/− cells (Figure 4D; P < .05
and P < .01). We also isolated CD34+, CD133+, or CD34+CD133+
cells and grew them on Matrigel-coated plates. However, no capillary
tube formation was observed for up to 3 weeks with EGM or EGM
plus PCCM culture, suggesting that cell-cell interactions or cellular
microenvironment is important for rapid differentiation of EPCs into
endothelial cells and angiogenesis.
The effect of CXCR2 deficiency on endothelial cell differentia-
tion and angiogenesis was further examined in CXCR2 knockout
mice. Pancreatic cancer cells were implanted into the pancreas of
CXCR2−/−, CXCR2+/−, or CXCR2+/+ mice. CD31 staining was
performed on tumor tissues. We observed a significantly decreased
microvascular density in tumors grown in CXCR2−/− mice com-
pared with CXCR2+/+ mice (P = .03; Figure 4, E–G ). We also no-
ticed that many CD31-positive cells in all the tumors analyzed do
not form hollow lumens for capillary tube or veins in tumors grown
in CXCR2−/− mice (Figure 4F ) in contrast to CD31-positive cells
that formed normal vessels in tumors grown in CXCR2+/+ mice
(Figure 4E). Consistent with tumor microvascular density, the volume
of the tumor in CXCR2−/− mice (0.56 cm3) is significantly smaller
than in CXCR2+/+ mice (1.5 cm3, P < .01; Figure 4H). These data
indicate a critical role of CXCR2 on EPC proliferation, differentiation,
and normal vessel formation.
BM-Derived EPC Increased Pancreatic
Tumor Growth In Vivo
To analyze the functional significance of BM-derived EPC in pan-
creatic cancer growth in vivo, we isolated CD34+CD133+ cells from
wild-type littermate of CXCR2 mice. Mouse pancreatic cancer cells
were mixed with (100:1) or without (control) EPCs and implanted
into the mouse (four mice for each group) subcutaneously. We ob-
served an increased microvascular density and tumor growth when
cancer cells were mixed with EPCs (Figure 5, A and B) compared
with the control. These data suggest that BM-derived EPCs promote
pancreatic cancer growth.
Human Pancreatic Cancer Is Associated with Increased
Expression of EPC Markers CD133 and CD146
To identify EPCs in human pancreatic cancers and normal pan-
creas tissues, nine cases of paired tumor-pancreas, and eight cases of
unpaired tumors or normal paraffin-embedded pancreatic tissue were
used for immunohistochemistry. Both CD133 and CD146 staining
showed a membrane/cytoplasmic pattern (Figure 6). CD133-positive
cells were observed sparsely in the normal pancreas (Figure 6A, arrow)
but were increased in the stroma adjacent to cancer tissues (Figure 6B,
insert; higher magnification, ×400). CD133-positive cells were lim-
ited to stromal cells. There was no obvious CD133 immunoreactivity
in cancer cells. The CD146 staining was more intensive in tumor
stroma (Figure 6D) than in normal pancreas stroma (Figure 6C ).
CD146 staining was observed in stromal cells, capillaries, and veins
as well (Figure 6, C and D, arrow). The number of CD133+ cells
Figure 3. CXCR2 gene knockout reduced proliferation and differentiation of BM-derived EPC. (A) Cell proliferation of CXCR2 +/+, +/−, and
−/− cells. Values are mean tumor volume ± SD. (B–G) Differentiation of CXCR2 +/+ (B and E), +/− (A and F), and −/− cells (D and G)
grown on fibronectin-coated plate cultured with EGM (B, C, D) or EGM plus PCCM (E, F, G). *P < 01. Magnification, ×100.
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was increased in 9 (60%, P = .002) of 15 tumor specimens. Of 15 can-
cers, 11 (73.3%, P = .0002) showed increased CD146+ cells com-
pared to normal pancreas (Table 1). In addition, all six tumors with
CD133-positive cells were well to moderately differentiated, whereas
nine tumors with strong CD133 staining were poorly differentiated.
These data suggested that CD133 and CD146 might play a role in
human pancreatic cancer growth.
Discussion
In this study, we report that the circulating CD34+, CD117+, CD133+,
and CD146+ EPCs are decreased in the bone marrow and/or blood of
CXCR2 knockout mice in response to pancreatic cancer cell challenge.
Ablation of CXCR2 gene expression slowed proliferation, differentia-
tion, and vasculogenesis of BM-derived EPCs. BM-derived EPCs
increased tumor angiogenesis and pancreatic cancer growth in vivo.
Figure 4. CXCR2 gene knockout inhibited capillary tube formation in vitro, decreased tumor neovascularization and tumor growth in vivo.
(A–C) Capillary tube formation of BM-derived EPCs with CXCR2 +/+ (A), +/− (B) or−/− (C) grown on matrigel coated plate. Magnification,
100×. (D) Representative bar graph of capillary tube formation (E–G). Tumor vessel formation in CXCR2+/+ (E) and CXCR2−/− (F) mice and
the representative bar graph of microvascular density (G). (H) Representative bar graph of tumor volume. n = 3–4 mice per group. Magni-
fication, ×200. The values are mean volume ± SD. *P < .05, #P < .01.
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Human pancreatic cancer tissue revealed increased CD133+ and
CD146+ cells compared with normal pancreas.
Recent evidence indicates an important role of BM-derived EPCs
in tumor growth and metastasis. EPCs were demonstrated to in-
corporate into blood vessels of early stage tumor and contributed
to growth and metastasis in breast cancer, melanoma, lung cancer,
and insulinoma [13–16]. Ablation of EPC with anti–VE-cadherin,
an antibody specifically targeting VE-cadherin decreased tumor
vasculogenesis and markedly inhibited tumor growth [14]. In our
study, coinjection of pancreatic cancer cells with BM-derived CD34+
CD133+ EPCs increased microvascular density and tumor growth,
suggesting a role of BM-derived EPCs in tumor neovascularization
in pancreatic adenocarcinomas.
The molecular mechanism involved in EPC-induced tumor vas-
culogenesis is poorly understood. Vascular endothelial growth factor
(VEGF) and placental growth factor (PlGF) have been shown to
contribute to EPC mobilization and homing into tumors [27]. Several
reports suggested the implication of cytokines, chemokines, hypoxia-
inducible 1, integrin, and matrix metalloproteinase 9 (MMP9) in reg-
ulating tumor vasculogenesis [16,17,28–32]. Recent studies indicated
a role of CXC chemokine receptor ligands CXCL1, CXCL2, CXCL5,
and CXCL8 in BM-derived hematopoietic progenitor cell mobiliza-
tion. CXCL5/CXCR2 recruitGr-1+CD11b+ cells that have been shown
to be involved in neovascularization directly or indirectly and promote
tumor cell invasion and metastasis [28]. CXCL2 (Gro-β) rapidly
mobilized CD34+, SCA1+, and c-kit+ bone marrow cells [33],
whereas CXCL8 and CXCL1 are involved in the homing of EPC
into the ischemic myocardium [34]. Our data clearly showed that
CXCR2 is required for EPC mobilization during tumor growth, as the
levels of all four EPC markers, CD34, CD117, CD133, and CD146,
Figure 5. EPC increasedmicrovascular density and pancreatic cancer growth in vivo. CD34+CD133+ cells isolated fromwild-typemicewere
cotransplanted with mouse pancreatic cancer cells. (A) Microvascular density. (B) Tumor volume.
Figure 6. Immunohistochemical analysis of EPCs in human pancreatic cancer and matched normal pancreas tissue. CD133 staining in
normal pancreas (A) and cancer tissue (B). CD146 staining in normal pancreas (C) and cancer tissue (D). Magnification, ×200.
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were decreased in the circulation of tumor-bearing CXCR2−/− mice
compared to wild-type mice. Although the basal level of CD133 was
high in CXCR2−/− mice, the mobilization of CD133+ cells was still
impaired under pathologic condition, leading to a five-fold decrease in
blood of CXCR2−/− compared with that of CXCR2+/+ mice (Fig-
ure 2C ). CXCR2−/−mice have been shown to have increased number
of neutrophils and B cells but not T cells, suggesting that CXCR2may
play a role in hematopoiesis, myelopoiesis, and granulocyte differenti-
ation [35].
The impaired recruitment of hematopoietic progenitor cells in-
cluding EPCs in cardiac disease and cancer indicates a critical role
of CXCR2 in regulation of BM-derived progenitor cell mobilization
under pathologic conditions.
The spindle cell differentiation of BM-derived cells was noticed at
day 4 on fibronectin-coated culture plates. CXCR2 gene knockout
slowed cell differentiation (Figure 3). PCCM increased the number
of differentiated cells in CXCR2+/+ and CXCR2+/− but not in
CXCR2−/− mice. The reduced angiogenic ability of EPCs under a
CXCR2-deficient background was shown by a decreased capillary tube
formation (Figure 3). The abnormality of tumor vessel formation in
CXCR2−/− mice further indicates a role of CXCR2 in BM-derived
cell differentiation into endothelial cells and angiogenesis. The con-
tribution of BM-derived EPC to tumor growth has been demonstrated
in several cancer models [12–15]. By an alternative approach, we
conducted cotransplantation of EPC with pancreatic cancer cells and
observed increased microvascular density and accelerated tumor
growth, suggesting a role of EPC in cancer growth in our pancreatic
cancer model.
Clinical evidence demonstrated that EPC level is increased in
breast cancer [36], non–small cell lung cancer [37], lymphoma
[38], head and neck cancer [39], myeloma [40], and hepatocellular
carcinoma [41]. Furthermore, the EPC level is correlated with the
clinical stage in breast cancer [36] and patient survival in lung can-
cer [37]. The increased number of CD133+ and CD146+ EPCs in
patient pancreatic cancer tissues compared to normal pancreas tissue
indicates that EPC might be involved in tumor neovascularization in
human pancreatic cancer.
In summary, we have demonstrated that the BM-derived EPC
is implicated in pancreatic cancer growth. CXCR2 is required for
mobilization, proliferation, and differentiation of BM-derived CD34+,
CD117+, CD133+, or CD146+ EPCs. BM-derived EPCs play a role in
tumor neovascularization in pancreatic cancer. Our study also provides
a cellular mechanism for CXCR2 mediated tumor angiogenesis. Fur-
thermore, EPC may serve as a biomarker for tumor neovascularization
and pancreatic cancer progression. Targeted ablation of BM-derived
EPC may offer novel therapeutic strategy for tumor neovascularization
and cancer progression.
References
[1] Shantsila E, Watson T, Tse HF, and Lip GY (2007). Endothelial colony forming
units: are they a reliable marker of endothelial progenitor cell numbers? Ann
Med 39, 474–479.
[2] Lamagna C and Bergers G (2006). The bone marrow constitutes a reservoir of
pericyte progenitors. J Leukoc Biol 80, 677–681.
[3] Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber
HP, and Ferrara N (2007). Tumor refractoriness to anti-VEGF treatment is
mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 25, 911–920.
[4] Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A,
Buckanovich RJ, Holtz DO, Jenkins A, Na H, Zhang L, et al. (2004). Tumor-
infiltrating dendritic cell precursors recruited by a β-defensin contribute to
vasculogenesis under the influence of VEGF-A. Nat Med 10, 950–958.
[5] Au P, Tam J, Fukumura D, and Jain RK (2008). Bone marrow–derived mesen-
chymal stem cells facilitate engineering of long-lasting functional vasculature.
Blood 111, 4551–4558.
[6] Condeelis J and Pollard JW (2006). Macrophages: obligate partners for tumor
cell migration, invasion, and metastasis. Cell 124, 263–266.
[7] Asahara T,Murohara T, Sullivan A, Silver M, van der Zee R, Li T,Witzenbichler B,
Schatteman G, and Isner JM (1997). Isolation of putative progenitor endothelial
cells for angiogenesis. Science 275, 964–967.
[8] Wu X, Lensch MW, Wylie-Sears J, Daley GQ, and Bischoff J (2007). Hemogenic
endothelial progenitor cells isolated from human umbilical cord blood. Stem Cells
25, 2770–2776.
[9] Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M,
Magner M, and Isner JM (1999). Bone marrow origin of endothelial progenitor
cells responsible for postnatal vasculogenesis in physiological and pathological
neovascularization. Circ Res 85, 221–228.
[10] Bertolini F, Shaked Y, Mancuso P, and Kerbel RS (2006). The multifaceted
circulating endothelial cell in cancer: towards marker and target identification.
Nat Rev Cancer 6, 835–845.
[11] Ergun S, Hohn HP, Kilic N, Singer BB, and Tilki D (2008). Endothelial and
hematopoietic progenitor cells (EPCs and HPCs): hand in hand fate determining
partners for cancer cells. Stem Cell Rev 4, 169–177.
[12] Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B,
Marks W, Witte L, et al. (2001). Impaired recruitment of bone-marrow–derived
endothelial and hematopoietic precursor cells blocks tumor angiogenesis and
growth. Nat Med 7, 1194–1201.
[13] Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C,
MacDonald DD, Jin DK, Shido K, Kerns SA, et al. (2005). VEGFR1-positive
haematopoietic bone marrow progenitors initiate the pre-metastatic niche.
Nature 438, 820–827.
[14] Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, Gupta S, Heikamp E,
McDevitt MR, Scheinberg DA, Benezra R, et al. (2007). Bone marrow–
derived endothelial progenitor cells are a major determinant of nascent tumor
neovascularization. Genes Dev 21, 1546–1558.
[15] Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, and Mittal V
(2008). Endothelial progenitor cells control the angiogenic switch in mouse
lung metastasis. Science 319, 195–198.
[16] Spring H, Schuler T, Arnold B, Hammerling GJ, and Ganss R (2005). Chemo-
kines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci
USA 102, 18111–18116.
[17] Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, Song H, Vandenberg S,
Johnson RS, Werb Z, et al. (2008). HIF1α induces the recruitment of bone
Table 1. Increased CD133+ and CD146+ Cells in Patient Tumor Tissue.
EPC Marker Normal Cancer Normal Cancer
CD133+ CD133+* CD146+ CD146+†
Paired Sample
1 + + + ++
2 + + + +
3 − + + +++
4 − ++ − ++
5 − ++ − −
6 + ++ + +
7 + ++ − −
8 + ++ − ++
9 + +++ + ++
Unpaired Sample
10 + +
11 + −
12 ++ ++/+++
13 + ++/+++
14 + ++/+++
15 ++ +++
16 + ++
17 ++ ++
“−” indicates less than 1%; “+,” between 1% and 10%; “++,” greater than 10%; “+++,” greater than
50% staining of tumor stroma.
*P = .02.
†P = .002.
Translational Oncology Vol. 4, No. 1, 2011 CXCR2 Mobilizes Endothelial Progenitor Cell Li et al. 27
marrow–derived vascular modulatory cells to regulate tumor angiogenesis and
invasion. Cancer Cell 13, 206–220.
[18] Raman D, Baugher PJ, Thu YM, and Richmond A (2007). Role of chemokines
in tumor growth. Cancer Lett 256, 137–165.
[19] Singh S, Sadanandam A, and Singh RK (2007). Chemokines in tumor angio-
genesis and metastasis. Cancer Metastasis Rev 26, 453–467.
[20] Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS, and Yeudall WA
(2006). Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer
Res 66, 4279–4284.
[21] Manna SK and Ramesh GT (2005). Interleukin-8 induces nuclear transcription
factor-κB through a TRAF6-dependent pathway. J Biol Chem 280, 7010–7021.
[22] Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan
AM, and Macoska JA (2008). CXCL5 promotes prostate cancer progression.
Neoplasia 10, 244–254.
[23] Li A, Dubey S, Varney ML, Dave BJ, and Singh RK (2003). IL-8 directly
enhanced endothelial cell survival, proliferation, and matrix metalloproteinases
production and regulated angiogenesis. J Immunol 170, 3369–3376.
[24] Li A, Varney ML, and Singh RK (2001). Expression of interleukin 8 and its
receptors in human colon carcinoma cells with different metastatic potentials.
Clin Cancer Res 7, 3298–3304.
[25] Funahashi H, Satake M, Dawson D, Huynh NA, Reber HA, Hines OJ, and
Eibl G (2007). Delayed progression of pancreatic intraepithelial neoplasia in a
conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor.
Cancer Res 67, 7068–7071.
[26] Li A, Hasui K, Yonezawa S, Tanaka S, and Sato E (1999). Immunohistochemical
analysis of pericryptal fibroblast sheath and proliferating epithelial cells in human
colorectal adenomas and carcinomas with adenoma components. Pathol Int 49,
426–434.
[27] Li B, Sharpe EE, Maupin AB, Teleron AA, Pyle AL, Carmeliet P, and Young PP
(2006). VEGF and PlGF promote adult vasculogenesis by enhancing EPC re-
cruitment and vessel formation at the site of tumor neovascularization. FASEB J
20, 1495–1497.
[28] Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP,
Matrisian LM, Richmond A, Lin PC, et al. (2008). Abrogation of TGFβ signal-
ing in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote
metastasis. Cancer Cell 13, 23–35.
[29] Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT,
Amano H, Avecilla ST, Heissig B, et al. (2006). Cytokine-mediated deployment of
SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes.
Nat Med 12, 557–567.
[30] Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale
FV, van Bruggen N, et al. (2007). Bv8 regulates myeloid-cell–dependent tumour
angiogenesis. Nature 450, 825–831.
[31] Du R, Petritsch C, Lu K, Liu P, Haller A, Ganss R, Song H, Vandenberg S,
and Bergers G (2008). Matrix metalloproteinase-2 regulates vascular patterning
and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol 10,
254–264.
[32] Ahn GO and Brown JM (2008). Matrix metalloproteinase-9 is required for
tumor vasculogenesis but not for angiogenesis: role of bone marrow–derived
myelomonocytic cells. Cancer Cell 13, 193–205.
[33] Pelus LM and Fukuda S (2006). Peripheral blood stem cell mobilization: the
CXCR2 ligand GROβ rapidly mobilizes hematopoietic stem cells with en-
hanced engraftment properties. Exp Hematol 34, 1010–1020.
[34] Hristov M, Zernecke A, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig A,
and Weber C (2007). Importance of CXC chemokine receptor 2 in the homing
of human peripheral blood endothelial progenitor cells to sites of arterial injury.
Circ Res 100, 590–597.
[35] Cacalano G, Lee J, Kikly K, Ryan AM, Pitts-Meek S, Hultgren B, Wood WI,
and Moore MW (1994). Neutrophil and B cell expansion in mice that lack
the murine IL-8 receptor homolog. Science 265, 682–684.
[36] Naik RP, Jin D, Chuang E, Gold EG, Tousimis EA, Moore AL, Christos PJ,
de Dalmas T, Donovan D, Rafii S, et al. (2008). Circulating endothelial progen-
itor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res
Treat 107, 133–138.
[37] Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S, Kenessey I, Ostoros G,
Magyar M, Ladanyi A, et al. (2006). Identification and clinical significance of
circulating endothelial progenitor cells in human non–small cell lung cancer.
Cancer Res 66, 7341–7347.
[38] Igreja C, Courinha M, Cachaco AS, Pereira T, Cabecadas J, da Silva MG, and
Dias S (2007). Characterization and clinical relevance of circulating and biopsy-
derived endothelial progenitor cells in lymphoma patients. Haematologica 92,
469–477.
[39] Brunner M, Thurnher D, Heiduschka G, Grasl M, Brostjan C, and Erovic BM
(2008). Elevated levels of circulating endothelial progenitor cells in head and neck
cancer patients. J Surg Oncol 98, 545–550.
[40] Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L, Dai K,
Berenson JR, Hussain MM, Klueppelberg U, et al. (2005). Circulating endothelial
progenitor cells in multiple myeloma: implications and significance. Blood 105,
3286–3294.
[41] Yu D, Sun X, Qiu Y, Zhou J, Wu Y, Zhuang L, Chen J, and Ding Y (2007).
Identification and clinical significance of mobilized endothelial progenitor cells in
tumor vasculogenesis of hepatocellular carcinoma. Clin Cancer Res 13, 3814–3824.
28 CXCR2 Mobilizes Endothelial Progenitor Cell Li et al. Translational Oncology Vol. 4, No. 1, 2011
